Publications
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2020 | Publication without faculty affiliation
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial2019 | Publication without faculty affiliation
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publication without faculty affiliation
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery2019 | Publication without faculty affiliation
- Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial2019 | Publication without faculty affiliation
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2019 | Publication without faculty affiliation
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome2018 | Publication without faculty affiliation
- Immediate effect of fluvastatin on lipid levels in acute coronary syndrome2007 | Second Faculty of Medicine
- Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial) [ISRCTN81331696]2005 | Second Faculty of Medicine, First Faculty of Medicine, Faculty of Physical Education and Sport
Loading network view...
